Great reminder Narmac....

I forget which of Crestor/Lipitor was shown to have a signficantly higher RRR in phase 2, but no matter....

What I'm wondering is how the market might react if the overall number for RRR, which is how I assume Top-Line would be reported, if that overall number is maybe 28 or 29% but much higher in one group than the other.  That is if ther results broke down as something like 18% RRR in Crestor but a 40% RRR in Lipitor....

I'm assuming something like this is distinctly possible....which would mean (in this hypothetical) a near miss on Top-Line but a huge win in the Crestor/208 arm. 

If something like this were to happen....